TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03399136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
Study: NCT02723695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of postural performances
Description: Postural tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of postural performances
Description: Postural tests
Study: NCT03936283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
Study: NCT03683277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib/Pomalidomide/Dexamethasone
Description: Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21
Study: NCT01547585

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standardized soy containing muffin
Description: Standardized muffin containing two levels of soy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized soy containing muffin
Description: Standardized muffin containing two levels of soy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized soy containing muffin
Description: Standardized muffin containing two levels of soy
Study: NCT04354480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of matching placebo on Day 1.
Study: NCT03782402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Description: Cannabinoids with THC and CBD versus placebo cannabinoids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabinoids
Description: Cannabinoids with THC and CBD versus placebo cannabinoids
Study: NCT05067322

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Minecraft
Description: A game played within the videogame Minecraft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minecraft
Description: A game played within the videogame Minecraft
Study: NCT02616549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: A manual-based yoga program featuring a yoga-breathing meditation technique
Study: NCT04272658

Intervention type: DIAGNOSTIC_TEST
Intervention: value of 4D body-to-whole dynamic acquisition in FDG
Description: differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of ICI
Study: NCT04603131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Chikungunya virus vaccine 20 mcg
Description: 3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Chikungunya virus vaccine 30 mcg
Description: 3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Chikungunya virus vaccine 10 mcg
Description: 3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
Study: NCT03938779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pad test
Description: Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
Study: NCT02300948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PregVit® contains 1.1 mg of folic acid
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PregVit-folic 5® contains 5 mg of folic acid
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
Study: NCT02518997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental Reading Aloud
Description: Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
Study: NCT01224626

Intervention type: DRUG
Intervention: Zyvox (linezolid)
Description: Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
Study: NCT01737385

Intervention type: PROCEDURE
Intervention: Measurement with O2C
Description: Measurement of microcirculation using O2C light probes.

Intervention type: PROCEDURE
Intervention: Measurement with O2C
Description: Measurement of microcirculation using O2C light probes.

Intervention type: PROCEDURE
Intervention: Measurement with O2C
Description: Measurement of microcirculation using O2C light probes.

Intervention type: PROCEDURE
Intervention: Measurement with O2C
Description: Measurement of microcirculation using O2C light probes.
Study: NCT01496131

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
Study: NCT02614859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Observation and Bicalutamide
Description: Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Bicalutamide
Description: Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
Study: NCT02871778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.17% saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.17% saline)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.17% saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371 + HS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371 + HS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371 + HS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study: NCT04568278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePRO-CTCAE application
Description: The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
Study: NCT01329679

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Energy drink, 2oz twice daily for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water, lime juice and cherry flavoring
Study: NCT01375257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treatment with antibiotics for endocarditis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline treatment with parenteral antibiotics
Study: NCT02512809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT01396226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2927
Description: A single dose of AZD2927 administered as an iv infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo administered as an iv infusion
Study: NCT05784493

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study group
Description: Washing by heated saline group
Study: NCT00912197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligofructose
Description: Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
Study: NCT03965936

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lipofilling
Description: Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lipofilling enriched with adipose tissue derived stem cells
Description: Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region.
Study: NCT03440099

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance exercise training
Description: 16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
Study: NCT03979690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NISInspire-C System
Description: The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
Study: NCT01944683

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GGF2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Study: NCT00403676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up bu a nurse
Description: Follow up bu a nurse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up by a medical doctor
Description: Follow up by a medical doctor
Study: NCT01218464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional plus MSC treatment
Description: Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional plus pacebo treatment
Description: Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Study: NCT03975920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Restful Jaw Device
Description: The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
Study: NCT01713621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 is a novel synthetic trioxolane antimalarial agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 is a novel synthetic trioxolane antimalarial agent
Study: NCT05786079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Footstrike modification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT04300699

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Geriatric Assessment
Description: A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
Study: NCT01371136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curricular training
Description: Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver.
Study: NCT00474708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effexor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Study: NCT04035018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: The participants in the control group will be receive one or more physical therapy according to the physician's decision.
Study: NCT01030159

Intervention type: OTHER
Intervention: Adult Cancer Patients
Description: Tracking anemia management in Adult Cancer Patients
Study: NCT00480181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nabilone
Description: Cesamet (nabilone) capsules given at titrating dosages as per protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
Study: NCT00738153

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT03039231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freespira Breathing System
Description: Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
Study: NCT01444248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/ Metformin
Description: 4/1000mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride/ Metformin
Description: 4/1000mg bid
Study: NCT04519359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop NAs therapy
Description: Stop NAs therapy
Study: NCT03837782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgery
Description: Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
Study: NCT04312685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra II Programmable Pump system - Flowonix Medical
Description: This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
Study: NCT00290342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV
Description: 3 intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa
Description: 3 intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMOVAX Polio®
Description: 3 intramuscular injections